麦考酚酸酯治疗幼年特发性关节炎全身型的疗效分析

韩彤昕; 李彩凤; 王江; 邝伟英; 周怡芳; 邓江红

doi:10.7499/j.issn.1008-8830.2013.08.015

PDF(738 KB)

中国当代儿科杂志 ›› 2013, Vol. 15 ›› Issue (8) : 666-670. DOI: 10.7499/j.issn.1008-8830.2013.08.015

论著·临床研究

麦考酚酸酯治疗幼年特发性关节炎全身型的疗效分析

韩彤昕，李彩凤，王江，邝伟英，周怡芳，邓江红

作者信息 +

Clinical efficacy of mycophenolate mofetil in the treatment of systemic-onset juvenile idiopathic arthritis

HAN Tong-Xin, LI Cai-Feng, WANG Jiang, KUANG Wei-Ying, ZHOU Yi-Fang, DENG Jiang-Hong

Author information +

文章历史 +

摘要

目的：评价麦考酚酸酯（mycophenolate mofetil, MMF）治疗幼年特发性关节炎全身型（system onset juvenile idiopathic arthritis, SoJIA）的临床疗效。方法：35例确诊为SoJIA并初次接受治疗的患儿随机分为3组，即传统治疗方案组（对照组），15例；MMF 1 组：传统治疗方案治疗2周后，病情无缓解，加用MMF治疗，7例；MMF 2 组：采用非甾体抗炎药+泼尼松+MMF治疗方案，13例。观察3组患儿治疗后2、4、12周的症状、体征、实验室指标及不良反应，并随访3~6个月。结果：治疗前MMF2组病程显著长于对照组，差异有统计学意义（P<0.05）。治疗2周后，与对照组相比，MMF1组和MMF2组的泼尼松用量明显减少，ESR明显减低（P<0.05）；MMF1组患儿体温高于另两组（P<0.05）。治疗4周时，与对照组比较，MMF1组泼尼松用量减少（P<0.05），ESR降低（P<0.05）；MMF2组泼尼松用量减少，体温下降并恢复至正常，WBC值降低，ESR降低，铁蛋白降低，差异均具有统计学意义（P<0.05）；MMF1和MMF2组相比，MMF2组体温更低（P<0.05）。MMF治疗组均未出现MMF用药的副作用。结论：MMF联合治疗能更好地控制SoJIA患儿病情，更快缓解其临床症状，减少联合应用的糖皮质激素药物的剂量，并有良好的安全性。

Abstract

OBJECTIVE: To evaluate the clinical efficacy of mycophenolate mofetil (MMF) in the treatment of systemic-onset juvenile idiopathic arthritis (SoJIA). METHODS: Thirty-five patients with a confirmed diagnosis of SoJIA who had received initial treatment were randomly divided into control (n=15), MMF1 (n=7) and MMF2 groups (n=13). The control group received conventional treatment, the MMF1 group received MMF after 2 weeks of conventional treatment that had not led to remission, and the MMF2 group received combination therapy with non-steroidal anti-inflammatory drugs, prednisone and MMF. Symptoms, signs, laboratory indices, and adverse events were observed after 2, 4, and 12 weeks of treatment, and follow-up was performed for 3-6 months. RESULTS: Before treatment, the MMF2 group had a significantly longer disease course than the control group (P<0.05). After 2 weeks of treatment, the MMF1 and MMF2 groups had a significantly lower prednisone dose and erythrocyte sedimentation rate (ESR) than the control group (P<0.05). The MMF1 group had significantly higher body temperature than the other two groups (P<0.05). After 4 weeks of treatment, the MMF1 group had a significantly lower prednisone dose and ESR than the control group (P<0.05). The MMF2 group had a significantly lower prednisone dose, body temperature (recovery to normal), white blood cell count, ESR and serum ferritin concentration than the control group (P<0.05). Body temperature was significantly lower in the MMF2 group than in the MMF1 group (P<0.05). No adverse events were observed in either the MMF1 or MMF2 groups during treatment. CONCLUSONS: Combination therapy with MMF can lead to better control of the patient's condition, more rapid relief of clinical symptoms and reduced glucocorticoid dose. The therapy with MMF is safe in children.

导出引用

韩彤昕，李彩凤，王江，邝伟英，周怡芳，邓江红. 麦考酚酸酯治疗幼年特发性关节炎全身型的疗效分析[J]. 中国当代儿科杂志. 2013, 15(8): 666-670 https://doi.org/10.7499/j.issn.1008-8830.2013.08.015

HAN Tong-Xin, LI Cai-Feng, WANG Jiang, KUANG Wei-Ying, ZHOU Yi-Fang, DENG Jiang-Hong. Clinical efficacy of mycophenolate mofetil in the treatment of systemic-onset juvenile idiopathic arthritis[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(8): 666-670 https://doi.org/10.7499/j.issn.1008-8830.2013.08.015

参考文献

[1] 曹兰芳.全身型幼年特发性关节炎的诊治及预后[J]. 实用儿科临床杂志, 2012, 27(9): 725-728.

[2] 韩彤昕, 李彩凤, 王江, 邝伟英, 周怡芳. 沙利度胺治疗幼年特发性关节炎的效果分析[J]. 中国当代儿科杂志, 2011, 13(8): 631-634.

[3] 屠志强, 蔡宇波, 曹兰芳. 2011年美国风湿病学会关于幼年特发性关节炎的治疗建议[J] . 实用儿科临床杂志, 2011, 26(21): 1689-1692.

[4] Lenz O, Fornoni A, Contreras G. Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis[J]. Drugs, 2005, 65(17): 2429-2436.

[5] Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura[J]. Am J Hematol, 2006, 81(1): 19-25.

[6] Moudgil A, Bagga A, Jordan SC. Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions [J]. Pediatr Nephrol, 2005, 20(10): 1376-1381.

[7] 曾华松.幼年特发性关节炎国际分类标准及治疗[J].实用儿科临床杂志, 2011, 26(9): 721-724.

[8] The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation [J]. Transplantation, 1996, 61: 1029-1037.

[9] Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome [J]. Pediatr Nephrol, 2011, 26(10): 1823-1828.

[10] Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood [J]. Br J Ophthalmol, 2007, 91(3): 319-324.

[11] Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry[J]. J Rheumatol, 2012, 39(9): 1867-1874.

[12] Farruggia P, Macaluso A, Tropia S, Genova S, Paolicchi O, Di Marco F, et al. Effectiveness of cyclosporine and mycophenolate mofetil in a child with refractory evans syndrome [J]. Pediatr Rep, 2011, 3(2): 49-50.

[13] Ogimi C, Honma N, Tanaka R, Oh-ishi T. Mycophenolate mofetil therapy for juvenile dermatomyositis with immune thrombocytopenic purpura[J]. Mod Rheumatol, 2012, 22(2): 280-283.

[14] Baratta A, Camarillo D, Papa C, Treat JR, Payne AS, Rozenber SS, et al. Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF) [J]. Pediatr Dermatol, 2013, 30(2): 240-244.

[15] Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil [J]. Pediatr Dermatol, 2011, 28(6): 689-694.